Tianyin Pharmaceutical

Tianyin Pharmaceutical is a Chinese pharmaceutical company established in 1994 and headquartered in Chengdu, Sichuan. The company’s business has centered on the development, manufacture, and commercialization of generic pharmaceuticals and traditional Chinese medicines. Its portfolio has served a broad range of therapeutic areas, including internal medicine, gynecology, hepatology, otolaryngology, urology, neurology, gastroenterology, and orthopedics. The company’s operating structure has included Chengdu Tianyin Pharmaceutical Co., Ltd., identified as a subsidiary of Tianyin Pharmaceutical. The business has historically been associated with the American Stock Exchange under the ticker TPI, although the available reference material does not establish its current listing status. Its principal market has been China, where products have been evaluated within the country’s regulatory and reimbursement systems. A notable feature of Tianyin Pharmaceutical’s portfolio is its combination of conventional generic medicines and products based on traditional Chinese medicine formulations. Reference material identifies Ginkgo Mihuan Oral Liquid as one of the company’s important products, alongside Benorylate Granules, Xiaoyanlidan Tablets, Qijudihuang Mixture, Qianggan Syrup, and Kangjunxiaoyan capsules. These products address different therapeutic categories, including cardiovascular-related indications, liver health, inflammation, and other internal-medicine applications. By 2010, the company was reported to have 56 Chinese medicines and pharmaceutical products approved by China’s State Food and Drug Administration. Of those products, 23 were included in the National Medical Reimbursement List and seven were included in the Essential Drug List. Nearly half of the portfolio consisted of prescription medicines. These listings were significant because inclusion in national reimbursement and essential-medicine systems can support institutional procurement and patient access within China, although the reference material does not provide sales figures or market-share data. Tianyin also maintained a research and development pipeline. Seventeen products were described as pending regulatory approval in the available material, and the company was reported to cooperate with academic institutions including China Pharmaceutical University, Sichuan University, and Shaanxi University of Chinese Medicines. These relationships indicate an effort to combine pharmaceutical development with university-based research, particularly in a market where traditional Chinese medicine and modern pharmaceutical manufacturing operate alongside one another. Manufacturing quality and regulatory compliance were another documented area of activity. In September 2013, the company received official Good Manufacturing Practice certificates from Chinese Food and Drug Administration officials for both its pre-extraction plant and formulation facilities. In the same period, Ginkgo Mihuan Oral Liquid obtained inclusion in Guangdong Province’s Provincial Essential Drug List, following earlier inclusion in the corresponding lists of Henan, Shandong, Sichuan, and Chongqing. The available references do not provide sufficient information to determine the company’s current operations, ownership, financial condition, or corporate status.

Tianyin Pharmaceutical was established in 1994 and developed as a China-based pharmaceutical business headquartered in Chengdu, Sichuan. Its activities have focused on producing and commercializing generic medicines as well as traditional Chinese medicine products. The company’s portfolio has covered a wide group of medical specialties, including internal medicine, gynecology, hepatology, otolaryngology, urology, neurology, gastroenterology, and orthopedics. The company has operated through Chengdu Tianyin Pharmaceutical Co., Ltd., which is identified in reference material as a subsidiary. Public descriptions of the business associate Tianyin Pharmaceutical with the American Stock Exchange and the ticker TPI. The available material does not establish whether that listing remains active or describe any subsequent corporate restructuring, ownership change, merger, bankruptcy, or delisting. By 2010, Tianyin Pharmaceutical was reported to have 56 medicines approved by China’s State Food and Drug Administration. Twenty-three products were included in the National Medical Reimbursement List, while seven were included in China’s Essential Drug List. Nearly half of the portfolio was described as prescription medicine. These figures illustrate the company’s participation in China’s regulated pharmaceutical and public reimbursement environment, but the available source does not provide sufficient information to assess revenue, market share, or commercial performance. The company’s best-known documented products included Ginkgo Mihuan Oral Liquid, Benorylate Granules, Xiaoyanlidan Tablets, Qijudihuang Mixture, Qianggan Syrup, and Kangjunxiaoyan capsules. Ginkgo Mihuan Oral Liquid was associated with cardiovascular indications, while the other named products represented the company’s broader generic and traditional-medicine portfolio. The product range reflected Tianyin’s dual emphasis on conventional pharmaceutical formulations and traditional Chinese medicine preparations. Research and development formed another part of the company’s strategy. At the time covered by the reference material, 17 products were pending approval by the Chinese regulator. Tianyin was also reported to cooperate with China Pharmaceutical University, Sichuan University, and Shaanxi University of Chinese Medicines. These partnerships connected the company with academic institutions involved in pharmaceutical and traditional Chinese medicine research. Regulatory and manufacturing developments were documented in 2013. In September of that year, Tianyin received official GMP certificates for both its pre-extraction plant and formulation facilities from Chinese Food and Drug Administration officials. GMP certification provided evidence that the cited facilities had passed the relevant regulatory assessment at that time. Earlier in 2013, Ginkgo Mihuan Oral Liquid was added to Guangdong’s Provincial Essential Drug List. The product had previously been included in provincial or municipal essential-drug lists for Henan, Shandong, Sichuan, and Chongqing. The available reference material is concentrated on the company’s products, regulatory approvals, manufacturing qualifications, and research pipeline. It does not provide reliable current information about Tianyin Pharmaceutical’s leadership, ownership, website, financial results, present trading status, or whether all of the historical products and facilities remain active. Accordingly, the company’s current corporate status is recorded as unknown.

• 2013

  Ginkgo Mihuan Oral Liquid gains Guangdong essential-drug listing

  [1]Tianyin Pharmaceuticalen.wikipedia.org

  Ginkgo Mihuan Oral Liquid was added to Guangdong Province’s Provincial Essential Drug List after earlier inclusion in lists covering Henan, Shandong, Sichuan, and Chongqing.

• 2013

  Manufacturing facilities receive GMP certificates

  [1]Tianyin Pharmaceuticalen.wikipedia.org

  The company received official GMP certification for its pre-extraction plant and formulation facilities.

• 2010

  Documented portfolio and reimbursement coverage

  [1]Tianyin Pharmaceuticalen.wikipedia.org

  The company was reported to have 56 products approved by China’s State Food and Drug Administration, including 23 on the National Medical Reimbursement List and seven on the Essential Drug List.

• 1994

  Company established

  [1]Tianyin Pharmaceuticalen.wikipedia.org

  Tianyin Pharmaceutical was established in China and later became headquartered in Chengdu, Sichuan.

A China-focused pharmaceutical manufacturer combining generic medicines with traditional Chinese medicine products and serving a broad range of therapeutic areas.

• Traditional Chinese medicine oral liquid

  Ginkgo Mihuan Oral Liquid

  Ginkgo Mihuan Oral Liquid was identified as one of Tianyin Pharmaceutical’s major products and was associated with cardiovascular indications. Its documented regulatory reach included inclusion in essential-drug lists in Henan, Shandong, Sichuan, Chongqing, and Guangdong. The available material does not specify its formulation, dosage, current availability, or commercial performance.

• Pharmaceutical granules

  Benorylate Granules

  Benorylate Granules were listed among Tianyin Pharmaceutical’s major products. They represent the company’s conventional pharmaceutical offering in granule form. The available source identifies the product as part of the company’s portfolio but does not provide reliable detail on its approved indications, launch date, market distribution, or current status.

• Traditional Chinese medicine tablets

  Xiaoyanlidan Tablets

  Xiaoyanlidan Tablets were identified as a major Tianyin Pharmaceutical product. The product illustrates the company’s participation in the traditional Chinese medicine segment and its use of tablet formulations. The available reference does not establish the product’s precise indication, launch date, regulatory history beyond the general portfolio information, or present availability.

• Traditional Chinese medicine mixture

  Qijudihuang Mixture

  Qijudihuang Mixture was named among Tianyin Pharmaceutical’s principal products. It belongs to the company’s traditional Chinese medicine portfolio and is presented as a liquid mixture rather than a tablet, capsule, or granule. The supplied reference does not provide a verified indication, launch year, sales information, or current product status.

• Traditional Chinese medicine syrup

  Qianggan Syrup

  Qianggan Syrup was listed as one of Tianyin Pharmaceutical’s major products and reflects the company’s emphasis on traditional Chinese medicine preparations. The available material does not specify its precise therapeutic claims, regulatory milestones, introduction date, geographic distribution, or whether it remains in production.

• Pharmaceutical capsules

  Kangjunxiaoyan Capsules

  Kangjunxiaoyan Capsules were included in the reference list of Tianyin Pharmaceutical’s major products. The capsule product formed part of the company’s broader medicine portfolio, which covered inflammatory and other internal-medicine applications. No reliable information is supplied about its precise indication, launch date, reimbursement status, or current availability.

• 2013

  Manufacturing facilities pursue GMP certificationStrategy

  Background

  Tianyin Pharmaceutical operated pre-extraction and formulation facilities within China’s regulated pharmaceutical manufacturing system.

  Action taken

  The company obtained official GMP certificates for both facilities from Chinese Food and Drug Administration officials.

  Aftermath

  The certification documented regulatory approval of the cited facilities at that time. The available material does not describe later renewals, expansions, or commercial effects.

  Source

• 2013

  Expand provincial essential-drug access for Ginkgo Mihuan Oral LiquidOther

  Background

  Ginkgo Mihuan Oral Liquid had previously been included in essential-drug lists covering Henan, Shandong, Sichuan, and Chongqing.

  Action taken

  The product obtained Provincial Essential Drug List status in Guangdong.

  Aftermath

  The listing expanded the product’s documented presence in China’s provincial essential-medicine system. No sales or procurement consequences are provided.

  Source

1. 1Tianyin Pharmaceuticalen.wikipedia.org